Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Satietyde
- Development stage
- Unknown
- Lead developer
- Diabetology
- Modality
- Peptides
- Administration
- Oral
01
Overview
Satietyde is an oral GLP-1 receptor agonist being developed by Diabetology for the treatment of obesity. It utilizes the company's proprietary Axcess™ delivery technology to enable the oral administration of a low-dose (microdose) GLP-1-based peptide. Unlike high-dose oral GLP-1 analogs that aim for systemic absorption to mimic injectable levels, Satietyde is designed to activate GLP-1 signaling primarily to promote satiety and aid in weight management. The program is currently in Phase 2 development.
- Brand names
- Satietyde
- Other names
- oral GLP-1 microdose
02
Targets
Beyond the preview
Go deeper on Satietyde.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Satietyde.